PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsVon willebrand factor
Von willebrand factor human
Voncento (von willebrand factor human) is an unknown pharmaceutical. Von willebrand factor human was first approved as Voncento on 2013-08-12. It has been approved in Europe to treat hemophilia a and von willebrand diseases.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
Trade Name
FDA
EMA
Combinations
Wilate
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Coagulation factor viii complex (human)
+
Von willebrand factor
Tradename
Proper name
Company
Number
Date
Products
Wilatevon Willebrand Factor/Coagulation Factor VIII Complex (Human)OctapharmaA-125251 RX2010-12-20
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
von willebrand factor/coagulation factor viii complex (human)Biologic Licensing Application2010-08-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hemorrhageMP_0001914D006470R58
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
108 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Von willebrand diseasesD014842EFO_0003910D68.0261542147
Hemophilia aD006467EFO_0007267D663373924
HemorrhageD006470MP_0001914R5813138
Blood coagulation disordersD001778EFO_0009314D68.91157
Hemostatic disordersD0201411157
Hematologic diseasesD006402EFO_0005803D75.911
Blood platelet disordersD00179111
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MenorrhagiaD008595EFO_0003945N92.0123
Heart failureD006333HP_0001635I50123
Postpartum hemorrhageD006473O7211
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Thrombotic thrombocytopenic purpuraD011697M31.19314
PurpuraD011693HP_0000979D69.2314
Thrombocytopenic purpuraD011696213
Type 2 von willebrand diseaseD056728Orphanet_166081D68.02123
EmbolismD00461711
ThromboembolismD013923HP_000190711
Carotid stenosisD01689311
Intracranial embolismD020766EFO_1000991I6611
Vascular diseasesD014652EFO_0004264I7711
Thrombotic microangiopathiesD057049M31.111
Show 4 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 3 von willebrand diseaseD056729Orphanet_166096D68.03123
Indications Without Phase
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVon willebrand factor human
INN
Description
Voncento (von willebrand factor human) is an unknown pharmaceutical. Von willebrand factor human was first approved as Voncento on 2013-08-12. It has been approved in Europe to treat hemophilia a and von willebrand diseases.
Classification
Protein
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL4298126
ChEBI ID
PubChem CID
DrugBank
UNII ID
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 46,020 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,085 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use